[Systematic review and pharmacoeconomic evaluation of Qizhi Weitong Granules in treatment of functional dyspepsia].
Zhongguo Zhong Yao Za Zhi
; 47(18): 5106-5112, 2022 Sep.
Article
in Zh
| MEDLINE
| ID: mdl-36164921
ABSTRACT
This study aims to investigate the efficacy, safety, and cost-effecctiveness of Qizhi Weitong Granules in the treatment of functional dyspepsia. Specifically, two commonly used clinical protocols for the treatment of functional dyspepsia were selected Qizhi Weitong Granules+Mosapride vs Mosapride alone(control). Meta-analysis of previous clinical studies was performed to examine the efficacy and safety, and pharmacoeconomic evaluation was carried out according to the results of the Meta-analysis. The cost-effectiveness analysis was carried out to elucidated the incremental cost-effectiveness ratio(ICER), and the sensitivity was analyzed with tornado dia-gram and Monte Carlo simulation. The willingness-to-pay threshold of patients for functional dyspepsia was investigated and compared with the ICER to evaluate whether Qizhi Weitong Granules was cost-effective. The result showed that the effective rate of Qizhi Weitong Granules combined with Mosapride in the treatment of functional dyspepsia was 95.49%, which was higher than that of Mosapride alone(73.30%)(OR=8.52, 95%CI[4.36, 16.64])(P<0.000 1). The two groups showed no significant difference in safety. The price of Qizhi Weitong Granules+Mosapride was higher than that of Mosapride alone. The ICER was 640.29 CNY, 1 506.67 CNY lower than the willingness-to-pay threshold. The sensitivity analysis showed that the analysis results were relatively stable. Thus, Qizhi Weitong Granules+Mosapride is safe, effective, and economical in the treatment of functional dyspepsia, which should be further promoted in clinical settings.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dyspepsia
Type of study:
Guideline
/
Health_economic_evaluation
/
Prognostic_studies
/
Systematic_reviews
Aspects:
Patient_preference
Limits:
Humans
Language:
Zh
Journal:
Zhongguo Zhong Yao Za Zhi
Journal subject:
FARMACOLOGIA
/
TERAPIAS COMPLEMENTARES
Year:
2022
Document type:
Article
Affiliation country:
China